Search results

Skip to results

Area of interest

Area of interest

Type

Type

Status

Status

Last updated

Last updated

Guidance programme

Advice programme

Showing 6706 to 6720 of 8223 results

  1. Rucaparib for maintenance treatment of relapsed platinum-sensitive ovarian, fallopian tube or peritoneal cancer (TA611)

    This guidance has been updated and replaced by NICE technology appraisal guidance TA1007.

    Technology appraisal guidance
    Published
    13 November 2019

  2. The clinical effectiveness and cost effectiveness of routine anti-D prophylaxis for RhD-negative women in pregnancy (TA41)

    This guidance has been updated and replaced by NICE technology appraisal guidance 156. 

    Technology appraisal guidance
    Published
    27 May 2002

  3. Dabrafenib with trametinib for treating advanced metastatic BRAF V600E mutation-positive non-small-cell lung cancer (terminated appraisal) (TA564)

    This guidance has been updated and replaced by NICE technology appraisal guidance 898.

    Technology appraisal guidance
    Published
    27 February 2019

  4. Ruxolitinib for treating polycythaemia vera (terminated appraisal) (TA356)

    This guidance has been updated and replaced by NICE technology appraisal guidance TA921.

    Technology appraisal guidance
    Published
    23 September 2015

  5. MI – secondary prevention: Secondary prevention in primary and secondary care for patients following a myocardial infarction (CG48)

    This guidance has been updated and replaced by NICE guideline CG172.

    Clinical guideline
    Published
    23 May 2007

  6. Adalimumab, etanercept and infliximab for ankylosing spondylitis (TA143)

    This guidance has been updated and replaced by NICE technology appraisal guidance 383.

    Technology appraisal guidance
    Published
    28 May 2008

  7. Epoetin alfa, epoetin beta and darbepoetin alfa for cancer treatment-induced anaemia (TA142)

    This guidance has been replaced by NICE technology appraisal guidance 323.

    Technology appraisal guidance
    Published
    28 May 2008

  8. Docetaxel, paclitaxel, gemcitabine and vinorelbine for the treatment of non-small cell lung cancer (TA26)

    This guidance has been replaced by NICE guideline CG24 [Replaced by NICE guideline CG121].

    Technology appraisal guidance
    Published
    26 June 2001

  9. Moderately to severely active ulcerative colitis: adalimumab (ESNM6)

    This evidence summary has been replaced by NICE technology appraisal guidance 329.

    Evidence summary
    Published
    2 November 2012

  10. Type 2 diabetes: dulaglutide (ESNM59)

    This evidence summary has been updated and replaced by NICE guideline NG28.

    Evidence summary
    Published
    16 June 2015

  11. Lorlatinib for untreated ALK-positive advanced non-small-cell lung cancer (TA909)

    This guidance has been updated and replaced by NICE technology appraisal guidance 1103.

    Technology appraisal guidance
    Published
    12 July 2023

  12. Smoking: harm reduction (QS92)

    This quality standard has been updated and replaced by NICE quality standard 207.

    Quality standard
    Published
    2 July 2015

  13. Obesity in children and young people: prevention and lifestyle weight management programmes (QS94)

    This quality standard has been updated and replaced by NICE quality standard 212.

    Quality standard
    Published
    23 July 2015

  14. Obesity in adults: prevention and lifestyle weight management programmes (QS111)

    This quality standard has been updated and replaced by NICE quality standard 212.

    Quality standard
    Published
    19 January 2016

  15. Diabetes in adults (QS6)

    This quality standard is updated and replaced by the quality standards on type 1 diabetes in adults (QS208) and type 2 diabetes in adults (QS209).

    Quality standard
    Last updated
    18 August 2016